Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move: (TSXV: $KHRN.V) (TSX: $AVCN.CA) (TSXV: $NRTH.V) (OTC: $KALY)
Delta, Kelowna, BC –August 23, 2019 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM - cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Read this in full at https://www.investorideas.com/news/2019/cannabis-potcasts/08231KHRN-AVCN-NRTH-KALY.asp
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few early announcements.
But first, Geocann announced that the company has successfully commercialized the first CBG soft gel products that utilize the multi-patented VESIsorb® delivery system for optimal absorption and measured bioavailability. The initial step is utilizing proprietary extraction technology to isolate and concentrate the CBG that allows Geocann to use its technical formulation expertise to address the active ingredient’s performance as it relates to dissolution, absorption, and bioavailability.
The first of two formulations is a combination of CBG and cannabidiol (CBD) while the second is a mono-CBG formulation. Both products include strategic inclusions of beta-caryophyllene (BCP) which has been shown to have synergistic effects as agonists for the CB2, 5-HT1A and glycine receptors.
“These product launches further advance Geocann’s leadership position as product development specialists that provide science-backed solutions to the industry’s formulation challenges,” said Marc Weder, Chief Scientific Officer. “The marketplace is demanding advancements beyond just CBD products and we are supremely positioned to deliver these solutions with more than three decades of research and product development expertise.”
Weder states that while the interest is high to include CBG (and other emerging cannabinoids and terpenes) in new formulations, the poor solubility and dissolution must be addressed to provide superior product solutions with the optimized absorption, bioavailability, and maximum therapeutic benefits consumers are seeking.
“Geocann has accomplished these results and has successfully transferred a rigorous product development protocol to the large-scale commercial production of soft gel capsules, topicals, foods, beverages, and sublinguals that combine these active ingredients with the VESIsorb® technology,” said Weder.
Geocann has worldwide exclusivity for cannabinoids formulated with VESIsorb®, and the company is quickly partnering with strategic brand leaders in key channels of distribution to deliver its robust portfolio of patent-protected products.
“The combination of CBD, CBG, and BCP powered by VESIsorb® in an elegant soft gel capsule is an important industry milestone,” said Jesse Lopez, CEO and founder. “Geocann will continue to pioneer the advancement of new cannabinoids, like CBG, CBN, and THCV, as it’s a privilege to offer these first-to-market opportunities to our brand partners.”
Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) provided an update on its cultivation and production operations near Ibague, Colombia, where it has achieved significantly expanded analysis, extraction and purification capabilities across its cultivation facility.
Khiron currently owns and operates one of the most sophisticated medical cannabis cultivation and processing facilities in Latin America. Building on the completion of the facility announced on June 2, 2019, the state-of-the-art, 14,000 square foot GMP and ISO 17025 compliant lab now includes full capabilities in the following:
● Ultra high and High performance liquid chromatography ("UHPLC & HPLC") technology, gas chromatography technology, microbiology testing, and heavy metals for testing flower and extract samples –Through the use of these in-house techniques, Khiron can quickly and accurately analyze samples, identify active cannabis components, and ensure that the products are extracted and purified to meet local regulations on THC and CBD concentrations.
● Stability testing – Stability tests provide evidence on how cannabis products vary over a given time period and under the influence of environmental factors. Khiron currently has robust stability testing capacities in place, with studies designed to evaluate and ensure the quality, safety and efficacy of its products, across various stages of extraction, as well as final product. In Colombia, stability data is needed to receive quotas for the production and domestic commercialization of THC extracts. As part of the Company's commitment to high quality standards, stability testing for extracts and final products are necessary before shipping product to consumers.
● Vertical integration – Leveraging the Company's cultivation, extraction and purification capabilities, Khiron has the ability to manage all stages of cannabis production, from soil to flower to extract, entirely within its own facility. Its vertically integrated capabilities serve to maximize efficiency and reliability across the cannabis supply chain, allowing the Company to streamline operations as it moves towards the sale and distribution of its products.
Alvaro Torres, Khiron CEO and Director, stated, "With advanced analysis, extraction and purification capabilities in place, the company has performed the analytical and stability tests required by the authorities to launch medical products and we remain on track for full commercialization of the grow site, anticipated in Q3 2019. Our significant investment in the Company's Ibague facility, primarily to target a market of 6 million patients in Colombia, ensures Khiron remains focused on its core strategy to serve the domestic market in Latin America."
Through scalable and flexible operations, the Company has designed its cultivation capabilities to work within the most up-to-date country quota to meet domestic demand, including to serve more than 119,000 patients at the Company's IILANS clinics. Based on the total allocation to the country, the Government of Colombia allocates annual quotas reflecting the operational plan and production estimates as outlined in the licence submissions, with the ability to request additional capacity to meet market demands. Country production quotas for 2020 will be announced by the INCB in January 2020.
Avicanna Inc. (TSX: AVCN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products announced that its subsidiary, Santa Marta Golden Hemp S.A.S., has completed its first export of purified CBD from Colombia to Canada for research and development purposes.
Aras Azadian, Chief Executive Officer of Avicanna commented "We are thrilled to complete our first export and proud to be doing so into Canada. This is another validation of Avicanna's ability to execute on all of its verticals and demonstrates the success and advantage of Avicanna's cultivation infrastructure, extraction and purification capacity, and regulatory expertise."
Health Canada issued three authorizations to SMGH on June 28, 2019 to allow for the import of CBD isolates and cannabis resin into Canada from Colombia for scientific purposes. The CBD isolates cleared Colombian border procedures and were exported from Colombia on August 22, 2019.
48North Cannabis Corp. (TSXV:NRTH) announced that it has entered into a definitive agreement dated August 22, 2019 to acquire Rare Industries, Inc. ("Quill"), a U.S. multi-state Vape Technology brand with product distribution in Oregon and Washington and near-term expansion plans for California and Nevada. The acquisition marks 48North's first foray into the United States.
Quill, a leader in the manufacturing of beautifully designed, lifestyle-focused and sleek vape products, specializes in the development of easy-to-use, controlled-dosage and health-focused disposable vape pens.
Quill distributes its unfinished branded proprietary vape delivery hardware to licensed cannabis processors who finish the products (including by filling the hardware with cannabis extracts) and distribute the finished products to licensed cannabis retailers. Quill is not itself engaged in the cultivation, distribution or possession of cannabis in the United States.
This year, in addition to Quill's established products, the company is launching a full-spectrum, hemp based, CBD-specific, internationally distributed, all-in-one vaporizer pen. As a result, 48North-owned products will now have multi-state distribution and the ability to be licensed globally, where legally permitted.
"48North recognizes the importance of entering the burgeoning U.S market. I believe that authentic brands and next-generation products distributed at scale, particularly in the emerging U.S. market, will be one of the major keys to success in the cannabis industry," said Alison Gordon, co-CEO of 48North.
"Without question, the Quill suite of products aligns closely with 48North's growing portfolio of brands. This acquisition marks a critical step in the Company's goal to become the trusted leader in the development, manufacturing and distribution of next-generation cannabis products and brands," Ms. Gordon continued.
48North intends to leverage Quill's expanding distribution network to accelerate the distribution of the Company's brand portfolio into the United States. 48North also intends to pursue opportunities to sell Quill products throughout its existing distribution network in Canada.
Kali-Extracts, Inc. (OTC: KALY) published a new website dedicated to providing information on the company’s recently introduced CBD Formulation, RespRx, for the treatment of Chronic Obstructive Pulmonary Disease (COPD) affecting 65 million people worldwide.
KALY introduced the new CBD Formulation earlier this week after making a patent application and trademark registration for the formulation. The website will be continually updated with information about the patent and application trademark progress and the ongoing RespRx medical trials and developments as the company advances toward FDA approval.
In the fourth quarter of last year, 2018, KALY acquired NCM Biotech (NCMB). NCMB owns and operates a U.S. Patent for cannabis extraction process. With the acquisition of NCMB, KALY is now primarily in the business of developing biopharmaceutical formulations from cannabis extractions for the treatment of various diseases. KALY now has over four years of research and development behind cannabis extract formulations targeting the treatment of Chronic Obstructive Pulmonary Disease (COPD), Cancer Pain Management, Type 2 Diabetes and Epilepsy.
KALY has implemented a long-term sustainable overall business strategy. KALY is not just relying on its biopharmaceutical development strategy alone to insure the company’s long-term success. KALY, through partnership and independently, has also introduced to market a number of CBD infused consumer food products and a new CBD extraction service for hemp farming operations.
The revenue realized in the first six months of 2019 comes primarily from KALY’s various CBD infusion offerings. KALY realized $165,000 in revenue in the first six months of 2019. The revenue results from the company’s cannabis business shift in the fourth quarter of last year. In the first six months of 2018, KALY reported only $46,000 in sales. The introduction of KALY’s new cannabis business has seen the company’s revenue grow over 250% in the first six months of 2019 compared to the first six months of 2018. KALY also realized $70,000 in operating net income in the first six months of 2019. KALY reported only nominal operating net income in the first six months of 2018.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
